The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.00
Bid: 44.50
Ask: 45.00
Change: -3.25 (-6.77%)
Spread: 0.50 (1.124%)
Open: 44.60
High: 46.00
Low: 44.60
Prev. Close: 48.00
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

14 Aug 2019 07:00

RNS Number : 9496I
Benchmark Holdings PLC
14 August 2019
 

Benchmark Holdings plc

("Benchmark" or the "Company") 

Directorate Change 

Benchmark Holdings plc (AIM: BMK), the aquaculture health, advanced nutrition, and genetics business, is pleased to announce the appointment of Septima Maguire as Chief Financial Officer. Septima is expected to commence her new role in November. Mark Plampin will remain with the business until January to ensure an effective transition.

Septima joins Benchmark from Dechra Pharmaceuticals PLC, the FTSE 250 international provider of specialist veterinary pharmaceuticals and related products, where she spent four years. Having joined as Group Financial Controller she was Acting Group Finance Director between 2016 and 2017. She was most recently Corporate Development Director overseeing all aspects of acquisition activities, strategic projects, business development and investment initiatives playing a significant role in supporting the company during a period of high growth.

 

Previously, Septima held a number of senior finance roles at Ardagh Group S.A., the international packaging manufacturer with revenues of €9.1bn, over a period of six years. She has also held finance roles at Impress Global, CHN Capital and PricewaterhouseCoopers. Septima holds a Masters in European Union Law from the University of Leicester and is ACCA qualified.

 

Malcolm Pye, Benchmark CEO commented: 

"We are delighted to have recruited someone of Septima's calibre. She has extensive strategic, investor and operational finance experience and proven expertise in driving improved business performance. She will be a valuable member of the leadership team as we focus on implementing structural and operational efficiencies and delivering on our five year strategy to drive future growth and profitability."

Peter George, Chairman commented:

"As Benchmark grows and moves from R&D spend to profit generating we need to balance our skill mix. Septima is an excellent addition to the management team and the Board is very pleased to announce this appointment."

 

The following information regarding the appointment of Septima Maguire, aged 42, is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM rules.

 

Current Directorships:

Dechra Finance Ireland DAC

  -ENDS-

 

 Enquiries:

 

Benchmark Holdings plc

Tel: 020 3915 1236

Malcolm Pye, CEO

 

Mark Plampin, CFO

 

Ivonne Cantu, Investor Relations

 

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black, Freddie Barnfield, Freddie Naylor-Leyland

 

MHP Communications

Tel: 020 3128 8742

Katie Hunt / Reg Hoare / Alistair de Kare-Silver benchmark@mphc.com

 

 About Benchmark Benchmark's mission is to enable food producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (artemia), sea lice treatments, training and data management tools. Find out more at www.benchmarkplc.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOADDGDIDGBBGCX
Date   Source Headline
17th Oct 20177:00 amRNSNew Vaccine Facility Delivers First Production
10th Oct 20172:41 pmRNSHolding(s) in Company
21st Sep 20177:00 amRNSBlock Listing Six Monthly Return
8th Sep 20177:00 amRNSTrading Update
22nd Aug 20177:00 amRNSRenewal of Sales and Marketing Agreement
16th Aug 20177:00 amRNSLaunch of breakthrough purification system
28th Jul 20172:57 pmRNSDirector leave of absence
27th Jun 20177:02 amRNSHalf-year Report
19th Jun 20173:00 pmRNSNotice of Results
25th May 20177:00 amRNSTrading Update and Notice of Results
2nd May 20177:00 amRNSTotal Voting Rights
26th Apr 201710:54 amRNSDirector Dealings
3rd Apr 20174:32 pmRNSBlock Listing Six Monthly Return
9th Mar 20178:44 amRNSDirector Share Options and Issue of Shares
7th Mar 201710:39 amRNSResult of AGM
7th Mar 20178:00 amRNSContract Win
2nd Mar 20173:34 pmRNSHolding(s) in Company
1st Mar 20172:09 pmRNSHolding(s) in Company
23rd Feb 20177:00 amRNSHolding(s) in Company
22nd Feb 20174:35 pmRNSHolding(s) in Company
16th Feb 20177:45 amRNSDirector Dealings
24th Jan 20177:00 amRNSFinal Results
3rd Jan 20177:00 amRNSTotal Voting Rights
1st Dec 20167:00 amRNSDirector/PDMR Shareholding
29th Nov 20167:00 amRNSCapital Markets Day
25th Nov 20167:00 amRNSAppointment of Non-Executive Director
23rd Nov 20164:52 pmRNSHolding(s) in Company
26th Oct 20167:00 amRNSTrading Statement
12th Oct 20167:00 amRNSBlock Admission Application
10th Oct 201612:02 pmRNSBlock listing Interim Review
31st Aug 20167:00 amRNSBenchmark secures innovative new equine vaccine
12th Aug 201612:41 pmRNSHolding(s) in Company
11th Aug 20167:00 amRNSAcq of South American shrimp breeding programme
10th Aug 20163:37 pmRNSHolding(s) in Company
10th Aug 20161:40 pmRNSHolding(s) in Company
10th Aug 20161:33 pmRNSHolding(s) in Company
10th Aug 20161:29 pmRNSHolding(s) in Company
9th Aug 20163:26 pmRNSHolding(s) in Company
5th Aug 20167:00 amRNSPlacing of 47.3 million new ordinary shares
29th Jul 20167:00 amRNSDirectorate Change
19th Jul 20167:00 amRNSNew Seabass Vaccine Commences Field Trials
12th Jul 20167:00 amRNSBreeding & Genetics Contract Win
28th Jun 20167:00 amRNSHalf-year Report
3rd Jun 20167:00 amRNSChange of Adviser
27th May 20167:00 amRNSChange of Auditor
26th May 20167:00 amRNSTrading Update and Notice of Results
22nd Apr 201610:45 amRNSHolding(s) in Company
18th Apr 20169:40 amRNSIssue of Equity
22nd Mar 20169:07 amRNSBlocklisting Interim Review
10th Mar 201610:13 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.